Biotechnology Weekly Briefs
Every published Biotechnology brief — the week’s developments and what they mean for operators, vendors, and investors.
- Platform-Buying Spree, Onshoring Control, and Diagnostics Gatekeeping Tighten Biopharma Value ChainsOctober 19, 2026
- Integrated discovery stacks, domestic IP control, and de-risked assets reshape biotech dealmakingOctober 12, 2026
- Platform Access Over Asset Buys, and Diagnostics AI as Oncology’s New MoatOctober 5, 2026
- Control Points Reprice Deals, Evidence Moats Tighten, and AI Moves Into ProductionSeptember 28, 2026
- Late-Stage Licensing, Recurring AI Platform Revenue, and Manufacturing Capacity Become the New MoatsSeptember 21, 2026
- Execution Risk Reprices Platform Bets, Clinical Proof Wins, and Capital Flows to De-Risked CatalystsSeptember 14, 2026
- Licensing Outpaces Equity, Capital Chases Inspection-Ready Manufacturing, and Biotech Monetizes PipelinesAugust 31, 2026
- Biosimilar rights become launch engines, AI enters regulated trial operations, and margins come under pressureAugust 24, 2026
- IP Clarity, Mega-Rounds, and Approval-Contingent Capital Redefine Biotech DealmakingAugust 17, 2026
- Execution Becomes the Moat, AI Moves into Workflow Control, and Commercial Infrastructure Commands the PremiumAugust 10, 2026
- Reserved capacity, state-backed biologics execution, and platform-premium M&A reshape dealmakingAugust 3, 2026
- Platform reproducibility, regulated in vivo editing, and late-stage assets are capturing the capital poolJuly 27, 2026